CSN-005 / CSN-006

About CuraSen Therapeutics

CuraSen Therapeutics is a clinical-stage biotech pioneering a novel approach to neurodegenerative and psychiatric diseases by targeting neuroinflammation and restoring key transmitter functionality. The company's lead programs are in Phase 2 development for conditions like neurogenic orthostatic hypotension and cognitive impairment associated with Parkinson's and Alzheimer's. As a privately held, pre-revenue entity, CuraSen is positioned to address a massive, underserved market with significant unmet need, though it faces the typical high-risk, high-reward landscape of CNS drug development.

About CuraSen Therapeutics

CuraSen Therapeutics is a clinical-stage biotech pioneering a novel approach to neurodegenerative and psychiatric diseases by targeting neuroinflammation and restoring key transmitter functionality. The company's lead programs are in Phase 2 development for conditions like neurogenic orthostatic hypotension and cognitive impairment associated with Parkinson's and Alzheimer's. As a privately held, pre-revenue entity, CuraSen is positioned to address a massive, underserved market with significant unmet need, though it faces the typical high-risk, high-reward landscape of CNS drug development.

About CuraSen Therapeutics

CuraSen Therapeutics is a clinical-stage biotech pioneering a novel approach to neurodegenerative and psychiatric diseases by targeting neuroinflammation and restoring key transmitter functionality. The company's lead programs are in Phase 2 development for conditions like neurogenic orthostatic hypotension and cognitive impairment associated with Parkinson's and Alzheimer's. As a privately held, pre-revenue entity, CuraSen is positioned to address a massive, underserved market with significant unmet need, though it faces the typical high-risk, high-reward landscape of CNS drug development.

Therapeutic Areas